• GPhC registered UK pharmacy
  • Free clinical support
  • Discreet delivery

Mounjaro, Wegovy and Mood: Anxiety and Depression Questions

Starting weight-loss treatment can be a hopeful moment, and for many people it brings a lift in confidence and energy. For others it brings a harder question: why do I feel low, flat or anxious, and is it the medicine? Reports about mood and GLP-1 medicines have been widely discussed, and it is natural to want a clear answer. This guide explains what the evidence and the regulators have said about depression, anxiety and suicidal thoughts with medicines such as Mounjaro and Wegovy, why mood can change during weight loss for reasons unrelated to the medicine, who should take extra care, what you can do, and how to get help quickly if you or someone you know is struggling.
Quick Answer

Can Mounjaro cause depression? Current evidence does not show that Mounjaro or Wegovy cause depression, anxiety or suicidal thoughts. Reviews of clinical trials and large studies have not found an increase, and in 2024 the European Medicines Agency’s safety committee concluded that the data did not support a causal link. However, mood can still change during treatment for other reasons, including rapid weight loss, eating much less, poor sleep, tiredness, body-image changes and underlying mental health conditions, and the studies have limits. If you notice persistent low mood, anxiety or loss of interest, tell your prescriber or GP. If you have thoughts of harming yourself, seek help immediately: call 999 in an emergency or Samaritans on 116 123, free at any time.

No causal link shownregulators and large reviews have not found that these medicines cause depression or suicidal thoughts
Mood can still changeweight loss, low intake, sleep and life events all affect how you feel
Help is availableSamaritans 116 123, free at any time; 999 in an emergency

IF YOU NEED HELP NOW

If you are thinking about harming yourself or ending your life, or you are worried about someone else, please get help now. In an emergency call 999 or go to A&E. You can call Samaritans free on 116 123 at any time, call NHS 111 and choose the mental health option, or text SHOUT to 85258. Tell someone you trust how you are feeling. You do not have to cope alone.

Why people ask about mood and GLP-1 medicines

Depression and anxiety are common in people living with obesity, and they can be affected by the experience of weight and stigma, as well as by medicines and treatment. When a medicine is taken by millions of people, some of them will develop low mood or have thoughts of self-harm simply by chance, because these problems are common anyway. Reports of such events with GLP-1 medicines prompted regulators in Europe and the United States to look closely at the data. Understanding what they found, and what the limits are, helps to separate a possible medicine effect from other causes.

What the evidence and regulators have found
SourceWhat it examinedWhat it concluded
European Medicines Agency safety committee (PRAC), April 2024Reports of suicidal thoughts and self-injury with GLP-1 receptor agonistsData did not support a causal association
Pooled analyses of randomised trials (several meta-analyses, 2024 to 2025)Tens of thousands of participants in placebo-controlled trialsNo increase in depression, anxiety or suicidal thoughts overall
Trial analyses of semaglutide and tirzepatide in obesityMood questionnaires and reports of suicidal ideationRates of suicidal ideation were similar to placebo; mood scores were stable or modestly better
Large real-world cohort studiesHealth records of people using different weight-loss medicinesMostly no increased risk after adjusting for other factors
US Food and Drug Administration, 2026Placebo-controlled trials and a large safety databaseReported no increased risk and asked for suicidal-behaviour warnings to be removed from some labels

These findings are reassuring, but they do not close the question completely, and it helps to know their limits.

  • Clinical trials often exclude people with severe depression, recent suicidal thoughts or other major mental illness, so they say less about the people at highest risk.
  • Trials of tirzepatide are fewer than those of semaglutide, and follow-up is often short.
  • Reports made to safety databases cannot prove cause, because they do not show how many people used a medicine and they are affected by publicity.
  • Observational studies can be affected by differences between the people compared.
  • Individual experiences matter even when averages are reassuring.

For the UK, the practical position is that Mounjaro and Wegovy carry their standard product information, which you should read in the patient leaflet. Anyone who experiences a new or worsening mood problem, or who suspects a side effect, can report it through the MHRA Yellow Card scheme.

Why mood can change during weight-loss treatment

Even if the medicine itself is not the cause, it makes sense that mood might change during a period of major physical change. Several factors are worth considering.

Possible factorHow it can affect moodWhat can help
Eating much lessLow energy and low intake affect concentration, irritability and moodRegular meals with protein; avoid very low intakes
Rapid weight loss and body-image changeAdjusting to a new body and others’ reactions can be unsettlingTalk about it; focus on health and function
Quieter “food noise”Food may have been a comfort or coping tool, and its absence can leave a gapFind other ways to relax and connect
Poor sleep and fatigueBoth are common on treatment and both lower moodSleep routine; see our fatigue guide
Nutrient gapsLow iron, vitamin B12 or vitamin D can contribute to low mood and tirednessBalanced diet; blood tests if symptoms persist
Dehydration and digestive side effectsFeeling unwell physically lowers moodFluids, symptom management
Hormonal changesThe menstrual cycle, perimenopause and thyroid changes can all affect moodDiscuss with your GP
Life events and stressWork, relationships, bereavement and health worriesSupport, talking therapies
Underlying depression or anxietyExisting conditions can fluctuate regardless of treatmentTell your prescriber and GP
AlcoholAlcohol affects mood and sleep, and treatment can change toleranceKeep within limits
Who should take extra care

If any of the following apply, tell your prescriber before starting treatment and mention any change in how you feel afterwards. This is not because the medicine is known to be unsafe for you, but because a good clinical conversation helps keep you safe.

  • You currently have depression, anxiety or another mental health condition, or have had one in the past.
  • You have ever had thoughts of harming yourself or ending your life.
  • You have a history of an eating disorder, such as anorexia, bulimia or binge-eating disorder. Treatment that reduces appetite needs careful thought in this situation.
  • You take antidepressants or other medicines that affect mood. Do not stop these without medical advice.
  • You are going through significant stress, grief or major life change.
  • You have a family history of mental health conditions.
What you can do

Notice and name changes early

  • Keep a short note of how you feel each week, along with sleep, appetite, energy and injection day. A pattern can help a clinician work out what is going on.
  • Ask someone close to you to tell you if they notice changes you might not see.
  • Take the changes seriously. Early conversations make things easier.

Look after the basics

  • Eat regularly and include protein. Very low intakes make mood and energy worse.
  • Drink fluids steadily and limit alcohol.
  • Protect sleep with a regular routine.
  • Move your body in ways you enjoy. Even a short walk can lift mood.
  • Stay connected with friends and family, even when you do not feel like it.

Get proper support

  • Speak to your GP or prescriber about how you feel. They can check for other causes, offer support and review your treatment.
  • In England, you can refer yourself to NHS Talking Therapies for anxiety and depression, without needing a GP referral. Similar services exist in the rest of the UK.
  • Charities such as Mind and Samaritans provide information and listening support.
  • If you are on antidepressants, keep taking them unless a doctor tells you otherwise.
Should I stop my treatment if I feel low?

This is a decision to make with a prescriber, rather than alone. If you feel your mood has changed since starting, or after a dose increase, contact your prescriber promptly. They may suggest pausing a dose increase, staying on a dose for longer, reviewing your eating, or in some cases stopping. Stopping suddenly can have its own effects, including returning appetite and weight regain, which can also affect mood. If you ever feel unsafe, seek help immediately rather than waiting for an appointment.

A note for family and friends
  • Look for changes such as withdrawal, irritability, loss of interest, sleeping or eating very differently, or talk of feeling hopeless.
  • Ask directly and kindly how they are. Asking about suicide does not put the idea in someone’s head.
  • Encourage them to speak to their GP or prescriber, and offer to go with them.
  • If you are worried that someone is in immediate danger, call 999.
When to get advice
SituationWhat to do
Feeling low, flat or anxious for more than two weeksSpeak to your GP or prescriber
Loss of interest in things you usually enjoy, or feeling hopelessSpeak to your GP or prescriber promptly
Panic, severe anxiety or agitation that is newContact your GP or NHS 111
Preoccupation with food, weight or body shape, or extreme restrictionSpeak to your GP promptly; support is available for eating difficulties
Thoughts of self-harm or ending your lifeCall 999, Samaritans on 116 123 or NHS 111 (mental health option) now
Questions to ask your prescriber
  • Does my mental health history change which treatment is suitable?
  • What should I watch for, and who should I contact if my mood changes?
  • Could my dose, eating or sleep be contributing?
  • Should I have blood tests to rule out other causes?
  • How do my other medicines interact with treatment?

The bottom line

The evidence so far does not show that Mounjaro or Wegovy cause depression, anxiety or suicidal thoughts, and the European safety committee reached that view in 2024. But mood can still change during treatment, for reasons that include eating much less, tiredness, poor sleep, nutrient gaps, body-image change and existing conditions, and the studies have limits. Notice changes early, look after the basics and talk to your prescriber or GP, and do not stop antidepressants without advice. If you ever have thoughts of harming yourself, call 999 or Samaritans on 116 123 straight away. Help is available and you do not have to cope alone.

Frequently Asked Questions
Can Mounjaro cause depression?
Current evidence does not show that Mounjaro causes depression. Mood can still change for other reasons during treatment, and any change should be discussed with a prescriber or GP.
Can Wegovy cause depression or anxiety?
Large reviews of trials have not found that GLP-1 medicines like Wegovy increase depression or anxiety overall. Individual experiences vary, so report any change.
Do GLP-1 medicines cause suicidal thoughts?
The European safety committee concluded in 2024 that the data did not support a causal link, and trial analyses have shown similar rates to placebo. If you have such thoughts, seek help immediately.
Why do I feel low on Mounjaro?
Possible reasons include eating very little, fatigue, poor sleep, nutrient gaps, body-image change, stress and existing mood conditions. A prescriber or GP can help work out the cause.
Can I take Mounjaro if I have depression?
Often yes, but tell your prescriber about your history, because treatment should be planned and monitored. Do not stop antidepressants without advice.
Can I take Mounjaro with antidepressants?
Many people do, but it needs a medicines review. Never stop an antidepressant on your own.
Does Mounjaro affect anxiety?
Some people notice anxiety linked to changes in eating, sleep or caffeine, or to health worries. Persistent anxiety should be discussed with your GP or prescriber.
Can weight loss itself change my mood?
Yes. Many people feel better, but body-image changes, loss of food as a comfort and rapid change can also be unsettling.
What if I have a history of an eating disorder?
Tell your prescriber. Treatment that reduces appetite needs careful consideration, and support from an eating-disorder service may be advised.
Should I stop Mounjaro if I feel low?
Speak to your prescriber first. They can review your dose and wellbeing and help you decide. Seek urgent help if you feel unsafe.
Where can I get help quickly?
Call 999 in an emergency, Samaritans on 116 123 at any time, NHS 111 (mental health option), or text SHOUT to 85258. You can also speak to your GP.
How do I report a side effect?
Through the MHRA Yellow Card scheme, online or via a healthcare professional.

Want to talk through how you are feeling on treatment?

Our GPhC-registered pharmacy team can talk through your medicines, your history and who to contact for support.

Start Your Free Online Consultation Use code SWITCH10 if you're switching from another provider Happy Pharmacy is a GPhC-registered pharmacy (No. 9013192). Superintendent Pharmacist: Palvinder Deol. Rated 4.8★ Excellent on Trustpilot

Medical disclaimer. This guide is for general information and is not a substitute for personal medical advice. Weight-loss medicines are prescription-only and are not suitable for everyone. If you are struggling with your mental health, speak to your GP or prescriber, and in an emergency call 999. Always follow the patient information leaflet and the advice of your prescriber or pharmacist.

  1. European Medicines Agency, Pharmacovigilance Risk Assessment Committee. Meeting highlights: review of suicidal thoughts and self-injury with GLP-1 receptor agonists. April 2024.
  2. Mounjaro (tirzepatide) KwikPen: UK Summary of Product Characteristics and patient information leaflet. electronic Medicines Compendium (emc).
  3. Wegovy (semaglutide) solution for injection in pre-filled pen: UK Summary of Product Characteristics and patient information leaflet. emc.
  4. Neuropsychiatric safety of GLP-1 receptor agonists and tirzepatide in adults with type 2 diabetes mellitus or obesity: review of randomised and observational evidence (PubMed Central, PMC13719276).
  5. US Food and Drug Administration. Safety review of GLP-1 receptor agonists and suicidal ideation and behaviour. 2026.
  6. NHS. NHS Talking Therapies for anxiety and depression.
  7. NHS. Help for suicidal thoughts.